DA-EPOCH-Rituximab/Metformin (RM) for Double Hit Lymphoma
Status:
Terminated
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
Newly diagnosed histologically confirmed c-myc+ de novo DLBCL. Metformin 500 mg daily x 1
week, then 500 mg twice daily (BID) x 2 weeks, then 850 mg twice daily until 1 month after
last cycle of chemo-immunotherapy.
DA-EPOCH-R every 21 days x 4 cycles (CNS prophylaxis single or triple therapy given
intrathecally each cycle to patients deemed appropriate by treating physician).
Restage after 4 cycles with CT. Complete remission or partial remission: complete 2 more
cycles or radiation therapy (XRT) consolidation per physician. Stable or progressive disease
will go on to salvage therapy off study.